Clinical trials: 13-valent Pneumococcal Vaccine
Fever After Vaccination, Fever
Fever After Simultaneous Versus Sequential Vaccination in Young Children
A prospective, randomized open-label clinical trial that will be conducted during the 2017-2018 influenza season. During the 2017-2018 season, approximately 280 children will be enrolled at Duke University Medical Center and…
- Conditions
- Fever After Vaccination, Fever, Febrile Seizure
- Trial name
- NCT03165981
- Testing
- PCV13, DTaP, IIV
- Where
- 3 sites in United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Duke University
Pneumococcal Vaccines, Pneumococcal Infections
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
The goal of this clinical trial is to evaluate the immunogenicity and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine…
- Trial name
- NCT06608199
- Testing
- pneumococcal disease prevention
- Where
- 3 sites in Indonesia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in…
- Trial name
- NCT00366678
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine, Pentavac
- Where
- 45 sites in France
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Influenza, Streptococcus Pneumoniae
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
Recent reviews have highlighted the unpredictability and complexity of immune interference when multivalent conjugate vaccines are co-administered with other pediatric vaccines.
- Trial name
- NCT02215863
- Testing
- Fluad and Prevenar13, Fluad, Prevenar13
- Where
- 3 sites in South Korea
- Volunteers
- 1,195 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Healthy Subjects
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.
- Trial name
- NCT00761631
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 36 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Pfizer
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccinations…
- Trial name
- NCT00368966
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7-valent Pneumococcal Conjugate Vaccine
- Where
- 41 sites in Spain
- Volunteers
- 619 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.
- Trial name
- NCT00508742
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 5 sites in Israel
- Volunteers
- 1,866 people, healthy volunteers welcome
- Sponsor
- Pfizer
Immunogenicity, Vaccine, Immunologic Memory
Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules
The purpose of this study is to evaluate the establishment of immunological memory between the 3 different infant vaccination schedules with the 13-valent pneumococcal conjugate vaccine (PCV13) currently in use.
- Trial name
- NCT03405805
- Testing
- 13-valent pneumococcal conjugate vaccine (PCV13)
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Community-acquired Pneumonia
Effectiveness of the PCV13 in Older Thai Adults
This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024.
- Trial name
- NCT06279624
- Where
- Thailand
- Volunteers
- 825 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Infection in Solid Organ Transplant Recipients
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
- Trial name
- NCT01527591
- Testing
- Pneumococcal Conjugate Vaccine 13 (PCV13)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.
- Trial name
- NCT00574795
- Testing
- 13vPnC
- Where
- 24 sites in Japan
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)
The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and…
- Trial name
- NCT01513551
- Testing
- Pneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13®
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate (13vPnC) vaccine in healthy Japanese adults aged >= 50 years.
- Trial name
- NCT00562354
- Testing
- 13vPnC
- Where
- 2 sites in Japan
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Pfizer
13-valent Pneumococcal Vaccine, Immunization
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during…
- Conditions
- 13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response
- Trial name
- NCT01026038
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 25 sites in France
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Vaccines
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
Pneumococcus is a group of bacteria that can cause pneumonia, meningitis and other diseases. These bacteria normally live in the nose of humans and are spread from person to person by touching or sneezing.
- Trial name
- NCT01953510
- Testing
- PCV10, PCV13
- Where
- Vietnam
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Pneumococcal Infections
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study…
- Trial name
- NCT00500266
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
- Where
- 59 sites in United States, Germany and 1 more
- Volunteers
- 1,053 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years.
- Trial name
- NCT06183216
- Testing
- Sinovac PCV13, PREVNAR 13
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Pneumonia, Meningitis
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
This study will evaluate the persistence of immunogenicity following a reduced dosing schedule of 10- or 13-valent Pneumococcal Conjugate Vaccine (PCV10, PCV13).
- Trial name
- PCV1+1_FU (NCT04275284)
- Testing
- PCV10, PCV13
- Where
- South Africa
- Volunteers
- 600 people
- Sponsor
- University of Witwatersrand, South Africa
Pneumococcal Infection
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
The proposed phase IIb randomized, open label, dose ranging, safety and immunogenicity study will evaluate two different doses of 13-valent pneumococcal conjugate vaccine (PCV13) in two groups of participants (55 through 74 years…
- Trial name
- NCT01654263
- Testing
- Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
- Where
- 7 sites in United States
- Volunteers
- 884 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)